Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies
- PMID: 16932688
- DOI: 10.1038/ncprheum0140
Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies
Erratum in
- Nat Clin Pract Rheumatol. 2006 Jul;2(7):398
Abstract
The signaling pathways involved in the immunobiology of polymyositis, dermatomyositis, and inclusion-body myositis are outlined in this Review, which is based on research performed during the past 10 years. In dermatomyositis, the complement cascade is activated and the expression of cytokines and chemokines is upregulated. In polymyositis and inclusion-body myositis, autoinvasive CD8+ T cells are clonally expanded. This T-cell subset possesses conserved amino-acid sequences in complementarity-determining region 3 of the T-cell receptor and, via the perforin pathway, exerts a myotoxic effect on muscle fibers that express major histocompatibility complex (MHC) class I molecules. In all inflammatory myopathies, molecules associated with T-cell transmigration and cytokine signaling, as well as chemokines and their receptors, are strongly expressed by endothelial and inflammatory cells. Early in the pathogenesis of polymyositis and inclusion-body myositis, expression of MHC class I molecules on muscle fibers is upregulated, even in the absence of autoinvasive CD8+ T cells. Emerging data indicate that such continuous upregulation of the expression of MHC class I molecules on muscle fibers leads to an endoplasmic reticulum stress response, intracellular accumulation of misfolded glycoproteins, and activation of nuclear factor kappaB pathways, which can further stimulate formation of MHC class I-CD8 complexes, resulting in a self-sustaining inflammatory response. Advances in our understanding of the signaling pathways involved in the pathogenesis of these inflammatory myopathies are expected to result in the identification of novel therapeutic targets for these diseases.
Similar articles
-
Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity.Brain. 2004 May;127(Pt 5):1182-90. doi: 10.1093/brain/awh148. Epub 2004 Mar 26. Brain. 2004. PMID: 15047591
-
Polymyositis and dermatomyositis.Lancet. 2003 Sep 20;362(9388):971-82. doi: 10.1016/S0140-6736(03)14368-1. Lancet. 2003. PMID: 14511932 Review.
-
Polymyositis mediated by T lymphocytes that express the gamma/delta receptor.N Engl J Med. 1991 Mar 28;324(13):877-81. doi: 10.1056/NEJM199103283241303. N Engl J Med. 1991. PMID: 1705662
-
Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis.Curr Opin Neurol. 2004 Oct;17(5):561-7. doi: 10.1097/00019052-200410000-00006. Curr Opin Neurol. 2004. PMID: 15367860 Review.
-
Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies.Muscle Nerve. 2003 Dec;28(6):659-82. doi: 10.1002/mus.10462. Muscle Nerve. 2003. PMID: 14639580 Review.
Cited by
-
Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.Int J Mol Sci. 2015 Aug 11;16(8):18683-713. doi: 10.3390/ijms160818683. Int J Mol Sci. 2015. PMID: 26270565 Free PMC article. Review.
-
Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis.Ann Neurol. 2017 Feb;81(2):227-239. doi: 10.1002/ana.24847. Epub 2017 Jan 27. Ann Neurol. 2017. PMID: 28009083 Free PMC article.
-
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.J Clin Invest. 2015 Dec;125(12):4612-24. doi: 10.1172/JCI81031. Epub 2015 Nov 9. J Clin Invest. 2015. PMID: 26551678 Free PMC article.
-
Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.Acta Myol. 2020 Dec 1;39(4):289-301. doi: 10.36185/2532-1900-032. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458584 Free PMC article. Review.
-
Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies.Arthritis Res Ther. 2024 Jul 30;26(1):144. doi: 10.1186/s13075-024-03364-z. Arthritis Res Ther. 2024. PMID: 39080801 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous